NXG Insider Trading

Insider Ownership Percentage: 36.68%
Insider Buying (Last 12 Months): C$33,600.00
Insider Selling (Last 12 Months): C$0.00

NexgenRx Insider Trading History Chart

This chart shows the insider buying and selling history at NexgenRx by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

NexgenRx Share Price & Price History

Current Price: C$0.27
Price Change: Price Decrease of -0.025 (-8.47%)
As of 07/25/2024 06:27 PM ET

This chart shows the closing price history over time for NXG up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

NexgenRx Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/24/2024Ronald Campbell LoucksDirectorBuy120,000C$0.28C$33,600.00
4/12/2022Kelly Tyler EhlerSenior OfficerBuy8,500C$0.33C$2,805.00261,500
9/22/2021Paul Everett CrossettInsiderBuy14,000C$0.36C$5,040.002,348,638
8/30/2021Paul Everett CrossettInsiderBuy3,000C$0.36C$1,065.002,304,638
See Full Table

SEC Filings (Institutional Ownership Changes) for NexgenRx (CVE:NXG)

NexgenRx Inc. administers, adjudicates, and pays drug, dental, and other extended health-care claims for the beneficiaries of health benefit plans underwritten by its customers in Canada. It offers NexSys claims management; NexAdmin plan administration; and NexPSPAssist patient support programs. NexgenRx Inc. was incorporated in 2003 and is headquartered in Toronto, Canada.
Read More on NexgenRx

Today's Range

Now: C$0.27
Low: C$0.27
High: C$0.27

50 Day Range

MA: C$0.28
Low: C$0.27
High: C$0.30

52 Week Range

Now: C$0.27
Low: C$0.18
High: C$0.35

Volume

15,500 shs

Average Volume

34,167 shs

Market Capitalization

C$19.15 million

P/E Ratio

N/A

Dividend Yield

4.17%

Beta

0.25

Who are the company insiders with the largest holdings of NexgenRx?

NexgenRx's top insider shareholders include:
  1. Ronald Campbell Loucks (Director)
Learn More about top insider investors at NexgenRx.